Arrowhead Pharmaceuticals

biopharmaceutical company

ARWR Nasdaq SEC CIK 879407 LEI 549300O3CSB8T7OZ3D66
Follow Arrowhead Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q4 2026 USD · US GAAP
Revenue, last quarter $37.8M −85.3% vs same quarter last year
Net income −$428M −1702.1% vs same quarter last year
EPS, diluted -
Operating cash flow −$192.4M −1039% vs same quarter last year
Revenue by quarter
$2.5M
$542.7M
$27.8M
$256.5M
$264M
$73.7M
$75.3M
$37.8M
Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26 Q4 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$1B−$500M$0$500M$1BFY12FY14FY16FY18FY20FY22FY24FY26
Show the numbers
YearRevenueNet income
FY26$450.8M−$724.2M
FY25$829.4M−$1.6M
FY24$3.6M−$599.5M
FY23$240.7M−$205.3M
FY22$243.2M−$176.1M
FY21$138.3M−$140.8M
FY20$88M−$84.6M
FY19$168.8M$68M
FY18$16.1M−$54.5M
FY17$31.4M−$34.4M
FY16$158.3K−$81.7M
FY15$382K−$91.9M
FY14$175K−$58.6M
FY13$290.3K−$31.1M
FY12$146.9K−$21.1M
MarginsShare of revenue
  • Operating margin
  • Net margin
−60000%−40000%−20000%0%20000%FY12FY14FY16FY18FY20FY22FY24FY26
Show the numbers
YearOperating marginNet margin
FY26−156.9%−160.6%
FY2511.9%−0.2%
FY24−16927.1%−16882.4%
FY23−85.2%−85.3%
FY22−73.4%−72.4%
FY21−107.8%−101.9%
FY20−105.9%−96.1%
FY1936.3%40.3%
FY18−346.5%−337.3%
FY17−117.8%−109.5%
FY16−51627.1%−51614.6%
FY15−25124.1%−24068.3%
FY14−30443.6%−33503%
FY13−8471.3%−10729.2%
FY12−14358.6%−14383.6%
Free cash flowOperating cash flow minus capital expenditure
−$800M−$600M−$400M−$200M$0$200MFY12FY14FY16FY18FY20FY22FY24FY26
Show the numbers
YearFree cash flow
FY26−$283.9M
FY25$156.9M
FY24−$604.3M
FY23−$330.6M
FY22−$188.9M
FY21$147.7M
FY20−$107.8M
FY19$161M
FY18−$48.6M
FY17−$31.9M
FY16−$68.3M
FY15−$67.7M
FY14−$37.1M
FY13−$19.3M
FY12−$15.8M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Arrowhead Pharmaceuticals
  • Healthcare median
−60000%−40000%−20000%0%20000%FY12FY14FY16FY18FY20FY22FY24FY26
Show the numbers
YearArrowhead PharmaceuticalsHealthcare median
FY26−160.6%−11.1%
FY25−0.2%−30.6%
FY24−16882.4%−47%
FY23−85.3%−58%
FY22−72.4%−80.4%
FY21−101.9%−71.9%
FY20−96.1%−62.2%
FY1940.3%−46.3%
FY18−337.3%−49.6%
FY17−109.5%−45.9%
FY16−51614.6%−36%
FY15−24068.3%−38.4%
FY14−33503%−35.5%
FY13−10729.2%−37.1%
FY12−14383.6%−29.1%